Traders Flee Pharma Junk Bonds as Price Scandal Engulfs Industry

  • Scrutiny spreads past $750-a-pill move by Shkreli's Turing
  • Lawmakers pump `fear into sector'; new deals await fate

Pharmaceutical companies are emerging as the latest pocket of sorrow in the beleaguered junk-bond market as a renewed public debate on drug-pricing tactics unnerves investors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.